National Specialized Hospital for Active Treatment of Hematologic Diseases
- Research works
- 116 ▲ 8% vs 2013–17
- Citations
- 647 5.6 per fractional work
- Top-10% rate
- 8.0% record average 16.5%
- Open access
- 67% world 28%
Not ranked overall: National Specialized Hospital for Active Treatment of Hematologic Diseases is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 8.1×. Every wedge is a field page.
- Immunology and Microbiology 8.1×
- Medicine 3.9×
- Biochemistry, Genetics and Molecular Biology 1.8×
- Dentistry 1.3×
- Neuroscience 0.8×
- Nursing 0.5×
- Pharmacology, Toxicology and Pharmaceutics 0.4×
- Chemistry 0.4×
- Health Professions 0.3×
- Psychology 0.2×
- Environmental Science 0.2×
- Physics and Astronomy 0.1×
- Social Sciences 0.1×
- Engineering 0.0×
Who are the top researchers at National Specialized Hospital for Active Treatment of Hematologic Diseases?
Ranked on the composite score, Margarita Guenova lead among researchers whose main affiliation is National Specialized Hospital for Active Treatment of Hematologic Diseases.
- 1 Margarita Guenova Bulgaria · #1,553,907 worldwide 6 citations · 17 works
Which keywords describe research at National Specialized Hospital for Active Treatment of Hematologic Diseases?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Prognostic Factors, Hematopoietic Stem Cells, Acute Myeloid Leukemia, AML, Immune Response, Mutation, Prognostic Scoring System and Antiretroviral Therapy.
- Stem Cell Regulation
- Patient Safety
- Fertility Preservation
- Rituximab
- Diagnosis Criteria
- Proteasome Inhibitors
- Immune Activation
- JAK2 Mutation
- BCR-ABL
- Resistance
- Prognostic Scoring System
- Antiretroviral Therapy
- Inflammation
- Acute Myeloid Leukemia
- Hematopoietic Stem Cells
- Prognostic Factors
- AML
- Immune Response
- Mutation
- Epidemiology
- Minimal Residual Disease
- Vaccine
- Imatinib
- Myelofibrosis
- Mesenchymal Stem Cells
- Cancer
- International Myeloma Working Group
- Clinical Trials
- Ovarian Tissue Cryopreservation
- Regulatory Challenges
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 30 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 30 words, with their numbers
- Prognostic Factors4▲ 26×3 topics
- Hematopoietic Stem Cells4▲ 131×3 topics
- AML3▲ 162×1 topic
- Acute Myeloid Leukemia3▲ 162×1 topic
- Immune Response3▲ 13×9 topics
- Inflammation2▲ 3.5×11 topics
- Mutation2▲ 31×3 topics
- Antiretroviral Therapy2▲ 32×4 topics
- Epidemiology2▲ 1.35×16 topics
- Prognostic Scoring System2▲ 132×2 topics
- Minimal Residual Disease2▲ 72×2 topics
- Resistance2▲ 47×2 topics
- Vaccine2▲ 11×3 topics
- BCR-ABL1▲ 154×1 topic
- Imatinib1▲ 154×1 topic
- JAK2 Mutation1▲ 177×1 topic
- Myelofibrosis1▲ 177×1 topic
- Immune Activation1▲ 48×2 topics
- Mesenchymal Stem Cells1▲ 37×2 topics
- Proteasome Inhibitors1▲ 52×2 topics
- Cancer1▲ 2.5×6 topics
- Diagnosis Criteria1▲ 98×1 topic
- International Myeloma Working Group1▲ 98×1 topic
- Rituximab1▲ 21×2 topics
- Clinical Trials1▲ 4.5×3 topics
- Fertility Preservation1▲ 52×1 topic
- Ovarian Tissue Cryopreservation1▲ 52×1 topic
- Patient Safety1▲ 20×1 topic
- Regulatory Challenges1▲ 34×2 topics
- Stem Cell Regulation1▲ 127×1 topic
Which research topics does National Specialized Hospital for Active Treatment of Hematologic Diseases publish most on?
By volume in 2022–2025: Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment and Multiple Myeloma Research and Treatments.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Acute Myeloid Leukemia Research Hematology 3 works
- 2 Chronic Myeloid Leukemia Treatments Hematology 1 works
- 3 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 1 works
- 4 Multiple Myeloma Research and Treatments Hematology 1 works
- 5 Biomedical Ethics and Regulation Physiology 1 works
- 6 Reproductive Biology and Fertility Public Health, Environmental and Occupational Health 1 works
- 7 HIV Research and Treatment Virology 1 works
- 8 Hematopoietic Stem Cell Transplantation Hematology 1 works
- 9 Hemophilia Treatment and Research Hematology 1 works
- 10 Chronic Lymphocytic Leukemia Research Genetics 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has National Specialized Hospital for Active Treatment of Hematologic Diseases's research output changed?
Output in 2018–2022 was 8% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Sofia
- Bulgarian Academy of Sciences
- Sofia University "St. Kliment Ohridski"
- Technical University of Sofia
- Medical University of Sofia
- Institute of Chemical Engineering
- Institute for Literature
- Institute of Mathematics and Informatics
- Georgi Nadjakov Institute of Solid State Physics
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.